Related Experiment Video

Updated: Jun 11, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Alzheimer's disease: clinical trials and drug development

Francesca Mangialasche1, Alina Solomon, Bengt Winblad

  • 1Aging Research Center, Karolinska Institutet, Stockholm, Sweden.

The Lancet. Neurology
|July 9, 2010
PubMed

Insights

Developing effective Alzheimer's disease treatments requires reconsidering drug development strategies. Acknowledging the complexity of Alzheimer's disease pathogenesis may reveal pharmacological interactions for better therapeutic approaches.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Alzheimer's disease is the leading cause of dementia in older adults.
  • Current Alzheimer's disease therapies offer symptomatic relief but lack disease-modifying capabilities.
  • Past research successes and failures highlight potential issues in understanding pathogenesis, diagnosis, and clinical trial design.

Purpose of the Study:

  • To analyze current research on Alzheimer's disease (AD) to identify potential improvements in drug development.
  • To discuss the limitations of current therapeutic strategies and the need for a revised approach.
  • To emphasize the importance of preclinical research and collaborative efforts in advancing AD treatment.

Main Methods:

  • Review of existing clinical and experimental studies on Alzheimer's disease.
  • Analysis of successes and failures in AD drug development.
  • Examination of ongoing randomized controlled trials and preclinical research findings.

Main Results:

  • Symptomatic treatments for Alzheimer's disease have seen some success, but disease-modifying therapies have largely failed.
  • Deficiencies in understanding AD pathogenesis, diagnosis, target selection, and trial design may contribute to therapeutic failures.
  • Preclinical research suggests complex pharmacological interactions, rather than single targets, may be key to effective treatment.

Conclusions:

  • A single cure for Alzheimer's disease is unlikely; a paradigm shift in drug development is necessary.
  • Focusing on patterns of pharmacological interactions, informed by preclinical research, may yield better therapeutic outcomes.
  • Enhanced collaboration among pharmaceutical, basic, and clinical researchers is crucial for optimizing Alzheimer's disease treatment approaches.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...